Please ensure Javascript is enabled for purposes of website accessibility

Celgene's Been Selling Shares in This Biotech

By Todd Campbell - Jan 24, 2018 at 7:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite working on revolutionary new treatments, this company may have fallen out of favor with Celgene.

Celgene Corp(CELG) has struck deals to acquire two biotech stocks this year, and since it's collaborating with some of the most intriguing young biotech stocks in the world, it has plenty of takeover candidates it can still consider. However, it doesn't look as if CRISPR Therapeutics (CRSP 2.78%) will be one of them. Celgene's been selling shares in that company since November.

Positioning itself for growth

Among its big-cap biotech peers, Celgene arguably boasts one of the most intriguing investment portfolios. It's long considered collaborations, including equity investments, as a key cog in its R&D strategy, and as a result, it's invested over $1 billion in a slate of emerging biotech stocks.

A person in a lab coat points to a double helix among a row of double helixes.


Celgene's investments are concentrated in blood disease, which isn't surprising given Celgene gets the bulk of its sales from drugs used to treat multiple myeloma, a type of cancer that forms in plasma cells. Celgene also tends to invest in game-changing companies working on drugs that can either expand its moat or move it into adjacent markets.

Perhaps there's no better example of its investment approach than Juno Therapeutics, which Celgene has just acquired for $9 billion. Before its acquisition, Celgene already owned almost 10% of Juno so that it could profit from Juno's research into chimeric antigen receptor T-cell therapies, or CAR-T, gene therapies. CAR-Ts were unproven when Celgene acquired its stake in Juno in 2015, but they're considered one of the most important advances in advanced B-cell cancer treatment today.

Falling out of favor?

Celgene usually invests with a buy-and-hold mentality, so its decision to sell CRISPR Therapeutics is notable.

CRISPR Therapeutics is one of only a handful of biotech companies developing a gene-editing technique called CRISPR-Cas9, which uses enzymes to cut away damaged genetic code to restore normal gene activity. It's thought that CRISPR-Cas9 could one day be used to overcome genetic mutations associated with many diseases; however, this research is only in its early stages. 

In a move that's similar to how it approached CAR-T, Celgene acquired 4 million CRISPR Therapeutics shares in 2015 to get in on the ground floor of this research, and as of October 2016, Celgene owned 4.8 million shares, representing 12.3% of CRISPR Therapeutics' outstanding shares.

Celgene's interest in CRISPR Therapeutics appears to be waning. In early December, Celgene reported it had sold 1.1 million shares for $21.1 million in November, and in late December, it reported it had sold another 415,715 shares worth $8.2 million. Altogether, those sales reduced Celgene's ownership of CRISPR Therapeutics to about 3.3 million shares, or 8.1% of CRISPR Therapeutics shares outstanding.

At first blush, the selling suggests Celgene's souring on CRISPR-Cas9; however, it may be more reasonable to think that Celgene's selling is because of its decision to buy Juno Therapeutics, which has ties to Editas (EDIT -0.22%), a CRISPR Therapeutics competitor.

Juno Therapeutics has been working Editas since 2015, when it inked an exclusive agreement to leverage Editas CRISPR-Cas9 research to create next-generation CAR-Ts that can penetrate tumors. In August, Editas reported it had won a $2.5 million milestone payment from Juno for its progress toward overcoming the tumor microenvironment with CAR-T and T-cell receptor strategies, and previously, Editas said it's making progress toward achieving T-cell persistence, which is important in tackling tumors.

What's next

Editas may be becoming Celgene's preferred CRISPR/Cas9 partner, but that doesn't necessarily mean Celgene will sell all of its remaining CRISPR Therapeutics shares. Celgene could decide to sell remaining shares to take advantage of CRISPR Therapeutics' recent share price rally, or it could keep its remaining shares so that it can play both sides of the field. Regardless of what Celgene decides to do from here, it doesn't appear to me that the company is any less interested in CRISPR-Cas9. Instead, its deal with Juno has me thinking it's one of the best positioned to benefit if CRISPR/Cas9 is a success.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celgene Corporation Stock Quote
Celgene Corporation
Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
$13.47 (-0.22%) $0.03
CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
$66.96 (2.78%) $1.81

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.